(CIDRAP News) The National Institute of Allergy and Infectious Diseases (NIAID) has launched a clinical trial of a dengue virus vaccine, a product that eventually may help prevent a disease to which 2.5 billion people are exposed.
The launching of a trial at the Johns Hopkins Bloomberg School of Public in Baltimore and the University of Vermont in Burlington follows more than a decade of development, the NIAID said in a press release.